The Russian vaccine against coronavirus infection “EpiVacCorona” has passed the registration procedure in Turkmenistan, Orient reports.
Turkmenistan became the first state after the manufacturing country to approve the use of this vaccine.
The document authorizing the purchase and use of the drug was issued by the Center for Registration of Medicines and State Control under the Ministry of Health and Medical Industry of Turkmenistan. This was preceded by an expert analysis of the pharmacological and pharmacopoeial committees of the Center.
At the end of September 2020, the coronavirus vaccine developed by the State Research Center for Virology and Biotechnology “Vector” was registered with Rospatent. The drug was named “EpiVacCorona”, which means “epitope vaccine against coronavirus”. The vaccine contains fragments of the virus - synthetic peptide antigens. They trigger the body's immune response against COVID-19.
According to Rospotrebnadzor (The Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing), the immunological effectiveness of the “EpiVacCorona” vaccine is 100%. These are the data from the results of the first and second phases of clinical trials.
At the moment, the “EpiVacCorona” vaccine has been released into civil circulation only in small batches. Its large-scale release should begin in February 2021.
Recall that on January 18, the Russian vaccine against COVID-19 “Sputnik V” from the Moscow center named after Gamaleya was registered in Turkmenistan. Its overall effectiveness was estimated at 91.4% (versus severe cases - 100%).